These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27631593)

  • 21. The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings.
    Sezaki H; Suzuki F; Hosaka T; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    Liver Int; 2017 Sep; 37(9):1325-1333. PubMed ID: 28178397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1.
    Kosaka K; Imamura M; Hayes CN; Abe H; Hiraga N; Yoshimi S; Murakami E; Kawaoka T; Tsuge M; Aikata H; Miki D; Ochi H; Matsui H; Kanai A; Inaba T; Chayama K
    J Viral Hepat; 2015 Feb; 22(2):158-65. PubMed ID: 24943406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response.
    Hong CM; Liu CJ; Yeh SH; Chen PJ
    J Formos Med Assoc; 2017 Apr; 116(4):295-299. PubMed ID: 28034492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis.
    Lee BS; Song MJ; Kwon JH; Lee TH; Jang JW; Kim SH; Lee SH; Kim HS; Kim JH; Kim SB; Ko SY; Song DS
    Gut Liver; 2019 Mar; 13(2):191-196. PubMed ID: 30400729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir.
    McPhee F; Hernandez D; Yu F; Ueland J; Monikowski A; Carifa A; Falk P; Wang C; Fridell R; Eley T; Zhou N; Gardiner D
    Hepatology; 2013 Sep; 58(3):902-11. PubMed ID: 23504694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection.
    Kinugasa H; Ikeda F; Takaguchi K; Mori C; Matsubara T; Shiraha H; Takaki A; Iwasaki Y; Toyooka S; Yamamoto K
    Antivir Ther; 2016; 21(1):37-44. PubMed ID: 26115551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms.
    McPhee F; Suzuki Y; Toyota J; Karino Y; Chayama K; Kawakami Y; Yu ML; Ahn SH; Ishikawa H; Bhore R; Zhou N; Hernandez D; Mendez P; Kumada H
    Adv Ther; 2015 Jul; 32(7):637-49. PubMed ID: 26155891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan.
    Suzuki F; Hatanaka N; Bando E; Nakamura K; Komoto A
    Hepatol Int; 2018 May; 12(3):244-253. PubMed ID: 29900486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained virological response after a 17-day treatment with daclatasvir plus asunaprevir in a cirrhotic patient with hepatitis C virus genotype 1b and null response for peginterferon ribavirin therapy.
    Sato A; Ishii T; Adachi K; Kumon D; Tamura T; Noguchi Y; Matsumoto N; Okuse C
    Clin J Gastroenterol; 2016 Apr; 9(2):89-92. PubMed ID: 26896968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A-Y93.
    Ishigami M; Hayashi K; Honda T; Kuzuya T; Ishizu Y; Ishikawa T; Nakano I; Urano F; Kumada T; Yoshioka K; Hirooka Y; Goto H
    J Med Virol; 2018 Apr; 90(4):736-744. PubMed ID: 29111616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy.
    Uchida Y; Naiki K; Kouyama JI; Sugawara K; Nakao M; Motoya D; Inao M; Nakayama N; Imai Y; Tomiya T; Mochida S
    PLoS One; 2018; 13(10):e0205600. PubMed ID: 30308053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.
    Teraoka Y; Uchida T; Imamura M; Hiraga N; Osawa M; Kan H; Saito Y; Tsuge M; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
    J Gen Virol; 2018 Aug; 99(8):1058-1065. PubMed ID: 29916799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir.
    Hayes CN; Imamura M; Chayama K
    Expert Rev Gastroenterol Hepatol; 2017 Feb; 11(2):103-113. PubMed ID: 27936974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study.
    Shin SK; Lee JW; Ra H; Kwon OS; Shin JB; Jin YJ; Lee S; Han KJ; Kim YN; Kim TH; Kim YS; Kim JH
    J Korean Med Sci; 2019 Oct; 34(41):e264. PubMed ID: 31650719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world.
    Oh JY; Kim BS; Lee CH; Song JE; Lee HJ; Park JG; Hwang JS; Chung WJ; Jang BK; Kweon YO; Tak WY; Park SY; Jang SY; Suh JI; Kwak SG
    Korean J Intern Med; 2019 Jul; 34(4):794-801. PubMed ID: 29792020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
    Takaguchi K; Toyoda H; Tsutsui A; Suzuki Y; Nakamuta M; Imamura M; Senoh T; Nagano T; Tada T; Tachi Y; Hiraoka A; Michitaka K; Shibata H; Joko K; Okubo H; Tsuji K; Takaki S; Watanabe T; Ogawa C; Chayama K; Kumada T; Kudo M; Kumada H
    J Gastroenterol; 2019 Aug; 54(8):742-751. PubMed ID: 30848363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis.
    Wang HL; Lu X; Yang X; Xu N
    J Gastroenterol Hepatol; 2017 Jan; 32(1):45-52. PubMed ID: 27597318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance-associated substitution test.
    Jang ES; Kim KA; Kim YS; Kim IH; Lee BS; Lee YJ; Chung WJ; Jeong SH
    J Med Virol; 2019 Dec; 91(12):2158-2165. PubMed ID: 31452206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis.
    Miyazaki R; Miyagi K
    Ther Apher Dial; 2016 Oct; 20(5):462-467. PubMed ID: 27098678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease.
    Morisawa N; Koshima Y; Satoh JI; Maruyama Y; Kuriyama S; Yokoo T; Amemiya M
    Clin Exp Nephrol; 2017 Oct; 21(5):818-824. PubMed ID: 27771774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.